MiMedx Group, Inc.

MiMedx Group, Inc. is a biopharmaceutical company that develops and markets regenerative biomaterial products and bioimplants derived from human placental tissues, including amniotic membrane, birth tissues, human skin, and bone. Headquartered in Marietta, Georgia, the company's mission is to be a leading global provider of healing solutions through continuous innovation to restore quality of life.

MiMedx's product portfolio, processed using its proprietary PURION process, includes allografts such as EpiFix and AmnioFix, which are utilized for both external and internal applications. Other key products include AmnioCord, EpiBurn, EpiCord, EpiXpress, ChorioFix, Emerge, Celera, RegenKit Wound Gel, EpiEffect, AmnioBurn, AmnioEffect, AxioFill, Heliogen, G4Derm Plus, and Hydrelix. These products are primarily targeted at the wound care, burn, surgical, sports medicine, and orthopedics markets, with additional applications in ophthalmic surgery and dental fields.

Joseph H. Capper serves as the Chief Executive Officer, having been appointed in January 2023. In the first quarter of 2026, MiMedx reported a 33% year-over-year decrease in net sales, largely attributed to new Medicare reimbursement policies that significantly impacted the advanced wound care market, leading to a 60% decline in its wound business. Despite these challenges, the surgical business segment demonstrated growth, increasing by 13% year-over-year. The company has initiated a restructuring and cost reduction plan, anticipating $40 million in annualized savings, and projects a return to profitability by the third quarter of 2026, with full-year adjusted EBITDA expected to be approximately breakeven. MiMedx maintains a strong financial position with substantial cash and cash equivalents.